Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 21 tags : Fda save search
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 9.3%
H: 12.98%
C: 0.43%
fda fda fast track gene therapies fast track gene therapy therapy aav9 fast track designation designation
FDA Signs Off on Moderna, J&J Boosters and Mixed Doses
Published: 2021-10-21 (Crawled : 15:15) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.32%
H: 0.05%
C: -0.55%
fda
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
Published: 2021-10-21 (Crawled : 12:00) - biospace.com/
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -4.45%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.12%
H: 0.53%
C: 0.06%
fda phase 2 sensor acquired phase 2b hearing loss
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2021-10-21 (Crawled : 12:00) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 0.83%
H: 6.35%
C: 3.07%
crispr treatment fda orphan drug therapy drug designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.